Back to News
Dec 4, 2025 12:00 PM

Thermo Fisher Teams Up With UK Firm To Scale Genetic Heart Disease Screening

UK-based GENinCode PLC unveiled a wide-ranging commercial partnership with Thermo Fisher Scientific Inc (NYSE:TMO) to manufacture, sell, and distribute its CARDIO inCode-Score test.

TMO is lagging behind market performance. See what is driving the move here.

Agreement Details

The agreement covers the U.S., Europe, the Middle East, and the African region.

CARDIO inCode-Score is a clinically validated, commercially available polygenic risk score (PRS) based on DNA extracted from a simple saliva or blood sample. The extracted DNA is scored to identify an individual’s inherited genetic risk of heart disease, thereby enabling prevention through lifestyle change and/or treatment.

Also Read: Thermo Fisher’s Upbeat Earnings Suggest Worst Is Over For Scientific Tools Sector, Analyst Says

Before the U.S. Food & Drug Administration (FDA) approval, laboratories will be introduced to CARDIO inCode-Score as a Lab Developed ...